
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
LabCorp has announced the launch of a new test that can be used to assess the capacity of antibodies in patient plasma to inhibit the SARS-CoV-2 virus. This neutralizing antibody test will be available to biopharmaceutical companies, hospitals, blood banks and other plasma-screening facilities.
For more information, click






